VJHemOnc is committed to improving our service to you

ASCO 2020 | Initial results of the phase III BOSTON study

VJHemOnc is committed to improving our service to you

Meletios Dimopoulos

Meletios Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece, gives an update on data from the BOSTON study (NCT03110562) – the first phase III study to evaluate the clinical benefit of selinexor with bortezomib and dexamethasone (SVd) for relapsed/refractory multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter